Lexeo Therapeutics (LXEO) news
Recent news
Lexeo Therapeutics to buy Mantle Therapeutics
AInvest Wire · Sep 22, 2026Lexo Therapeutics: Deal includes up to $13 mln in milestone payments, total potential $21.30 mln
Lexeo Therapeutics, Inc. (Nasdaq: LXEO) has disclosed a deal structure that includes up to $13 million in milestone payments, with a total potential value of $21.3 million. The company has not provided specific details regarding the nature of the agreement or the conditions under which the…
AInvest Wire · Sep 22, 2026Lexeo Therapeutics, - To pay $8.30 mln upfront to Mantle shareholders
AInvest Wire · Sep 22, 2026Lexeo: Sunrise-FA 2 study for LX2006 on track to initiate in 2Q
Lexeo Therapeutics is progressing with its clinical development program for LX2006, an AAV-based gene therapy candidate for Friedreich’s ataxia cardiomyopathy. Following positive interim data from the ongoing Phase 1/2 SUNRISE-FA trial and alignment with the FDA on key parameters for the…
AInvest Wire · Jun 17, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.